

---

---

**Cardiovascular implants — Cardiac  
valve prostheses —**

**Part 1:  
General requirements**

*Implants cardiovasculaires — Prothèses valvulaires —  
Partie 1: Exigences générales*



This document is a preview generated by EBS



**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2015, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
Ch. de Blandonnet 8 • CP 401  
CH-1214 Vernier, Geneva, Switzerland  
Tel. +41 22 749 01 11  
Fax +41 22 749 09 47  
copyright@iso.org  
www.iso.org

# Contents

	Page
Foreword.....	iv
Introduction.....	v
<b>1 Scope.....</b>	<b>1</b>
<b>2 Normative references.....</b>	<b>1</b>
<b>3 Terms and definitions.....</b>	<b>2</b>
<b>4 Abbreviations.....</b>	<b>11</b>
<b>5 Fundamental requirements.....</b>	<b>12</b>
<b>6 Device description.....</b>	<b>12</b>
6.1 Intended use.....	12
6.2 Design inputs.....	12
6.2.1 Operational specifications.....	12
6.2.2 Performance specifications.....	12
6.2.3 Implant procedure.....	12
6.2.4 Packaging, labelling, and sterilization.....	13
6.3 Design outputs.....	13
6.4 Design transfer (manufacturing verification/validation).....	14
6.5 Risk management.....	14
<b>7 Design verification testing and analysis/design validation.....</b>	<b>15</b>
7.1 General requirements.....	15
7.2 <i>In vitro</i> assessment.....	15
7.3 Preclinical <i>in vivo</i> evaluation.....	15
7.4 Clinical investigations.....	15
<b>Annex A (informative) Rationale for the provisions of this part of ISO 5840.....</b>	<b>16</b>
<b>Annex B (normative) Packaging.....</b>	<b>19</b>
<b>Annex C (normative) Product labels, instructions for use, and training.....</b>	<b>20</b>
<b>Annex D (normative) Sterilization.....</b>	<b>23</b>
<b>Annex E (informative) <i>In vitro</i> test guidelines for paediatric devices.....</b>	<b>24</b>
<b>Annex F (informative) Statistical procedures when using <i>in vitro</i> performance criteria.....</b>	<b>28</b>
<b>Annex G (informative) Examples and definitions of some physical and material properties of heart valve systems.....</b>	<b>29</b>
<b>Annex H (informative) Examples of standards applicable to testing of materials and components of heart valve systems.....</b>	<b>40</b>
<b>Annex I (informative) Raw and post-conditioning mechanical properties for support structure materials.....</b>	<b>46</b>
<b>Annex J (informative) Corrosion assessment.....</b>	<b>48</b>
<b>Annex K (informative) Echocardiographic protocol.....</b>	<b>51</b>
<b>Bibliography.....</b>	<b>54</b>

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see [www.iso.org/directives](http://www.iso.org/directives)).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see [www.iso.org/patents](http://www.iso.org/patents)).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the WTO principles in the Technical Barriers to Trade (TBT) see the following URL: [Foreword - Supplementary Information](#)

The committee responsible for this document is ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*.

This first edition of ISO 5840-1, together with ISO 5840-2 and ISO 5840-3, cancels and replaces ISO 5840:2005, which has been technically revised.

ISO 5840 consists of the following parts, under the general title *Cardiovascular implants — Cardiac valve prostheses*:

- *Part 1: General requirements*
- *Part 2: Surgically implanted heart valve substitutes*
- *Part 3: Heart valve substitutes implanted by transcatheter techniques*

## Introduction

There is, as yet, no heart valve substitute which can be regarded as ideal.

The ISO 5840-series has been prepared by a group well aware of the issues associated with heart valve substitutes and their development. In several areas, the provisions of the ISO 5840-series deliberately have not been specified to encourage development and innovation. It does specify the types of tests, test methods, and/or requirements for test apparatus and requires documentation of test methods and results. The areas with which the ISO 5840-series are concerned are those which will ensure that associated risks to the patient and other users of the device have been adequately mitigated, facilitate quality assurance, aid the clinician in choosing a heart valve substitute, and ensure that the device will be presented at the operating table in convenient form. Emphasis has been placed on specifying types of *in vitro* testing, on preclinical *in vivo* and clinical evaluations, on reporting of all *in vitro*, preclinical *in vivo*, and clinical evaluations, and on the labelling and packaging of the device. Such a process involving *in vitro*, preclinical *in vivo*, and clinical evaluations is intended to clarify the required procedures prior to market release and to enable prompt identification and management of any subsequent problems.

With regard to *in vitro* testing and reporting, apart from basic material testing for mechanical, physical, chemical, and biocompatibility characteristics, the ISO 5840-series also covers important hydrodynamic and durability characteristics of heart valve substitutes. The ISO 5840-series does not specify exact test methods for hydrodynamic and durability testing, but it offers guidelines for the test apparatus.

The ISO 5840-series is incomplete in several areas. It is intended to be revised, updated, and/or amended as knowledge and techniques in heart valve substitute technology improve.



# Cardiovascular implants — Cardiac valve prostheses —

## Part 1: General requirements

### 1 Scope

This part of ISO 5840 is applicable to heart valve substitutes intended for human implantation and provides general requirements. Subsequent parts of the ISO 5840-series provide specific requirements.

This part of ISO 5840 is applicable to both newly developed and modified heart valve substitutes and to the accessories, packaging, and labelling required for their implantation and for determining the appropriate size of the heart valve substitute to be implanted.

This part of ISO 5840 outlines an approach for qualifying the design and manufacture of a heart valve substitute through risk management. The selection of appropriate qualification tests and methods are derived from the risk assessment. The tests may include those to assess the physical, chemical, biological, and mechanical properties of heart valve substitutes and of their materials and components. The tests may also include those for preclinical *in vivo* evaluation and clinical evaluation of the finished heart valve substitute.

This part of ISO 5840 defines operational conditions for heart valve substitutes.

This part of ISO 5840 excludes homografts.

NOTE A rationale for the provisions of this part of ISO 5840 is given in [Annex A](#).

### 2 Normative references

The following documents, in whole or in part, are normatively referenced in this document and are indispensable for its application. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 5840-2, *Cardiovascular implants — Cardiac valve prostheses — Part 2: Surgically implanted heart valve substitutes*

ISO 5840-3, *Cardiovascular implants — Cardiac valve prostheses — Part 3: Heart valve substitutes implanted by transcatheter techniques*

ISO 11135, *Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices*

ISO 11137 (all parts), *Sterilization of health care products — Radiation*

ISO 11607 (all parts), *Packaging for terminally sterilized medical devices*

ISO 14155, *Clinical investigation of medical devices for human subjects — Good clinical practice*

ISO 14160, *Sterilization of health care products — Liquid chemical sterilizing agents for single-use medical devices utilizing animal tissues and their derivatives — Requirements for characterization, development, validation and routine control of a sterilization process for medical devices*

ISO 14630:2012, *Non-active surgical implants — General requirements*